Palmetto GBA has indicated that its medical directors reviewed the AxiaLIF clinical information and recommended coverage for the procedure, which has been supported in the literature as clinically effective. Palmetto provides care to approximately 9 million Medicare beneficiaries in seven states.
With the addition of Palmetto coverage beginning next year, AxiaLIF will be covered for approximately 23 million people nationwide.
Related Articles on Spine Devices:
VertiFlex Completes Superion Interspinous Trial Enrollment
Court Rules Spinal Kinetics Didn’t Infringe on Synthes Patent
LDR Moves Headquarters to Bigger Texas Facility
